| Date Filed | Type | Description |
| 10/06/2023 |
4
| Salzmann Peter (CEO) has filed a Form 4 on Immunovant, Inc.|
Txns:
| Sold 894 shares
@ $35.54, valued at
$31.8k
Sold 4,345 shares
@ $36.39, valued at
$158.1k
|
|
| 08/16/2023 |
4
| Salzmann Peter (CEO) has filed a Form 4 on Immunovant, Inc.|
Txns:
| Sold 91,744 shares
@ $21.34, valued at
$2M
Sold 11,314 shares
@ $22.04, valued at
$249.4k
|
|
| 08/08/2023 |
4
| Salzmann Peter (CEO) has filed a Form 4 on Immunovant, Inc.|
Txns:
| Sold 101,339 shares
@ $21.73, valued at
$2.2M
|
|
| 07/13/2023 |
4
| Salzmann Peter (CEO) has filed a Form 4 on Immunovant, Inc.|
Txns:
| Sold 3,233 shares
@ $19.73, valued at
$63.8k
|
|
| 04/19/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/14/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/13/2023 |
4
| Salzmann Peter (CEO) has filed a Form 4 on Immunovant, Inc.|
Txns:
| Sold 4,021 shares
@ $16.8, valued at
$67.6k
|
|
| 10/17/2022 |
4
| Salzmann Peter (CEO) has filed a Form 4 on Immunovant, Inc.|
Txns:
| Sold 2,793 shares
@ $9.18, valued at
$25.6k
|
|
| 09/29/2022 |
4
| Salzmann Peter (CEO) has filed a Form 4 on Immunovant, Inc.|
Txns:
| Sold 1,605 shares
@ $4.67, valued at
$7.5k
|
|
| 09/01/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/19/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/29/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/01/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/25/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/19/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/29/2022 |
4
| Salzmann Peter (CEO) has filed a Form 4 on Immunovant, Inc.|
Txns:
| Sold 1,622 shares
@ $4.72, valued at
$7.7k
|
|
| 04/14/2022 |
4
| Salzmann Peter (CEO) has filed a Form 4 on Immunovant, Inc.|
Txns:
| Sold 19,227 shares
@ $5.9, valued at
$113.4k
|
|
| 01/11/2022 |
4
| Salzmann Peter (CEO) has filed a Form 4 on Immunovant, Inc.|
Txns:
| Sold 125,158 shares
@ $7.25, valued at
$907.4k
|
|
| 09/14/2021 |
4
| Salzmann Peter (CEO) has filed a Form 4 on Immunovant, Inc.|
Txns:
| Granted 430,700 options to buy
@ $8.62, valued at
$3.7M
Disposed/sold 430,700 options to buy
@ $19.01, valued at
$8.2M
Granted 464,700 options to buy
@ $8.62, valued at
$4M
Disposed/sold 464,700 options to buy
@ $17, valued at
$7.9M
|
|
| 06/17/2021 |
4
| Salzmann Peter (Director) has filed a Form 4 on Corbus Pharmaceuticals Holdings, Inc.|
Txns:
| Granted 58,200 options to buy
@ $2.07, valued at
$120.5k
|
|
| 03/23/2021 |
4
| Salzmann Peter (CEO) has filed a Form 4 on Immunovant, Inc.|
Txns:
| Granted 132,500 shares
@ $0
Granted 464,700 options to buy
@ $17, valued at
$7.9M
|
|
| 05/22/2020 |
4
| Salzmann Peter (Director) has filed a Form 4 on Corbus Pharmaceuticals Holdings, Inc.|
Txns:
| Granted 40,500 options to buy
@ $7.3, valued at
$295.7k
|
|
| 05/18/2020 |
4
| Salzmann Peter (CEO) has filed a Form 4 on Immunovant, Inc.|
Txns:
| Granted 430,700 options to buy
@ $19.01, valued at
$8.2M
|
|
| 03/10/2020 |
4
| Salzmann Peter (Director) has filed a Form 4 on Corbus Pharmaceuticals Holdings, Inc.|
Txns:
| Granted 66,600 options to buy
@ $4.53, valued at
$301.7k
|
|
| 03/10/2020 |
3
| Salzmann Peter (Director) has filed a Form 3 on Corbus Pharmaceuticals Holdings, Inc. |
| 12/20/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/20/2019 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |